NCT01322451View on ClinicalTrials.gov

Oral Bioavailability of Two Solid Formulations of GLPG0259.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
Healthy
Interventions
DRUG

GLPG0259 fumarate

single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate

DRUG

GLPG0259 free base

single oral dose, GLPG0259, 50 mg solid formulation

Trial Locations (1)

Unknown

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY